title: Comparative resource utilization and costs for patients with acute coronary syndrome managed with percutaneous coronary intervention and treated with clopidogrel or prasugrel.
abstract: OBJECTIVE
  Results of a study of bleeding events and other inhospital outcomes with the use of clopidogrel versus prasugrel in patients with acute coronary syndrome (ACS) managed with percutaneous coronary intervention (PCI) are reported.
  
  
  METHODS
  Demographic and clinical data on adults hospitalized for ACS, managed with PCI, and treated with clopidogrel or prasugrel during a two-year period were extracted from a large hospital claims database. Bleeding rates, hospital length of stay (LOS), and total hospital costs during the index hospitalization were evaluated.
  
  
  RESULTS
  The study sample consisted of 75,297 patients who received clopidogrel and 9,477 who received prasugrel. The unadjusted bleeding rates were 5.7% with clopidogrel use and 3.2% with prasugrel use (p < 0.0001). After propensity score stratification to adjust for selection bias, rates of bleeding events were not significantly different between clopidogrel- and prasugrel-treated patients (odds ratio, 0.90; 95% confidence interval [CI], 0.80-1.02; p = 0.0949). The adjusted mean ± S.D. hospital LOS was 0.22 day lower (95% CI, 0.15-0.28; p < 0.001) with the use of prasugrel versus clopidogrel, and adjusted total mean hospital costs were $375 less for prasugrel-treated patients (p = 0.003).
  
  
  CONCLUSIONS
  After adjustments for demographic and clinical characteristics, rates of inhospital bleeding in patients who received prasugrel and those who received clopidogrel were not significantly different. The adjusted analyses showed that the mean hospital LOS was shorter and total mean hospital costs were lower for patients treated with prasugrel.
authors.affiliation: Eli Lilly and Company, Indianapolis, IN. bae_jay@lilly.com.
authors.forename: Jay P
authors.initials: JP
authors.lastname: Bae
authors.affiliation: Eli Lilly and Company, Indianapolis, IN.
authors.forename: Douglas E
authors.initials: DE
authors.lastname: Faries
authors.affiliation: Indegene Total Therapeutic Management, Kennesaw, GA.
authors.forename: Frank R
authors.initials: FR
authors.lastname: Ernst
authors.affiliation: Premier Research Services, Premier Healthcare Alliance, Charlotte, NC.
authors.forename: Craig
authors.initials: C
authors.lastname: Lipkin
authors.affiliation: Eli Lilly and Company, Indianapolis, IN.
authors.forename: Zhenxiang
authors.initials: Z
authors.lastname: Zhao
authors.affiliation: Comprehensive Health Insights, a Humana Company, Louisville, KY.
authors.forename: Chad
authors.initials: C
authors.lastname: Moretz
authors.affiliation: Eli Lilly and Company, Indianapolis, IN.
authors.forename: Hsiao D
authors.initials: HD
authors.lastname: Lieu
authors.affiliation: Eli Lilly and Company, Indianapolis, IN.
authors.forename: Mark B
authors.initials: MB
authors.lastname: Effron
mesh_terms: D054058:Acute Coronary Syndrome / Q000175:diagnosis / Q000191:economics* / Q000628:therapy; D000368:Aged; D000077144:Clopidogrel; D016208:Databases, Factual / Q000639:trends; D019468:Disease Management; D005260:Female; D006295:Health Resources / Q000191:economics / Q000639:trends; D006470:Hemorrhage / Q000139:chemically induced / Q000191:economics; D017721:Hospital Costs / Q000639:trends; D006801:Humans; D007902:Length of Stay / Q000639:trends; D008297:Male; D008875:Middle Aged; D062645:Percutaneous Coronary Intervention / Q000191:economics*; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D000068799:Prasugrel Hydrochloride / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D013988:Ticlopidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D000068799:Prasugrel Hydrochloride; D013988:Ticlopidine